← Back to home

AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 2 (DISORDER)

Clinical trials for AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 2 (DISORDER) explained in plain language.

Never miss a new study

Get alerted when new AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 2 (DISORDER) trials appear

Sign up with your email to follow new studies for AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 2 (DISORDER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Brain injection trial aims to slow Alzheimer's by targeting toxic protein

Disease control Recruiting now

This early-stage study is testing whether a new drug called NIO752 can reduce the brain's production of tau protein, which forms toxic tangles in Alzheimer's disease. Researchers will give the drug via spinal injection to 10 participants with mild to moderate Alzheimer's and meas…

Matched conditions: AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 2 (DISORDER)

Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 2 (DISORDER)

Get alerted when new AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 2 (DISORDER) trials appear

Brain injection trial aims to slow Alzheimer's by targeting toxic protein